through

Therefore, FcγRIIb expression provides a potential biomarker of response to rituximab and identifies patients for which treatment with non-internalising, so-called type II, anti-CD20 monoclonal antibodies may be preferable. A local collaboration with the Vision Laboratory, part of the Clinical Neurosciences Research Division and Southampton Eye Unit, has produced patents in […]